Medindia

X

Alere Inc. Declares Dividend on its Series B Convertible Perpetual Preferred Stock

Friday, May 20, 2011 General News J E 4
Advertisement


WALTHAM, Mass., May 19, 2011 Alere Inc. (NYSE: ALR), a global leader in enabling individuals to take charge of their health at home through the merger of rapid diagnostics and health management, has declared a dividend of $3.00 per share on its Series B Convertible Perpetual Preferred Stock (NYSE: ALR PR B). The dividend will be paid in shares of Series B stock in an amount per share equal to the quotient of (a) $3.00 divided by (b) 97% of the average of the volume-weighted average price per share of the Series B stock on the New York Stock Exchange for each of the five consecutive trading days ending on the second trading day immediately prior to the record date of the dividend. Alere will pay cash in lieu of any fractional shares resulting from the dividend. The dividend is payable on July 15, 2011 to holders of record of Series B stock at the close of business on July 1, 2011.

Such payment will cover the amount of all dividends accrued from April 1, 2011 through June 30, 2011.

For more information about Alere, please visit our website at http://www.alere.com.

By developing new capabilities in near-patient diagnosis, monitoring and health management, Alere enables individuals to take charge of improving their health and quality of life at home. Alere's global leading products and services, as well as its new product development efforts, focus on infectious disease, cardiology, oncology, drugs of abuse and women's health. Alere is headquartered in Waltham, Massachusetts.

SOURCE Alere Inc.
Advertisement


Advertisement

You May Also Like

Advertisement
View All

Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
User Avatar
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions
s
Renaissance Laser and Vein Institute Is a Premier ...
S
Global Biosimilars Industry